All In Biotech

Drug Trial Radar · NCT07946783

A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk

A Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Administration, Dose-escalation Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics Characteristics and the Effect of Food on Pharmacokinetics of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

103

Planned (sponsor's estimate)

Start

Nov 19, 2026

Primary completion

Sep 30, 2027

Study completion Dec 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study comprised of 3 parts, gradually investigating the safety, tolerance, PK and PD characteristics of the ZL-65 tablets in healthy adult participants and obesity with cardiovascular risk participants in Australia. The study results will provide important basis for formulating the subsequent study strategies and dosing plans.Part 1: Single-ascending Dose (SAD) study and Food Effect (FE) study;Part 2: Multiple-ascending Doses (MAD) study;Part 3: Obesity with cardiovascular risk study.

Conditions

  • Obesity With Cardiovascular Risk Study

Interventions

  • Single-ascending Dose (SAD) study and Food Effect (FE) studyDrug

    The SAD portion of the study consists of 5 cohorts. Dosing in these cohorts will precede sequentially: 5 mg, 10 mg, 25 mg, 40 mg and 50 mg cohorts.

  • Multiple-ascending Doses (MAD) studyDrug

    The MAD portion of the study consists of 3 cohorts. Dosing in these cohorts will precede sequentially:10 mg, 25 mg and 40 mg cohorts.

  • Obesity with cardiovascular risk studyDrug

    This study intends to set up 2 dose cohorts, temporarily as follows: 1) 10 mg QD cohort, 2) 25 mg QD cohort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Day 1 to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd Commercial Road

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.